<DOC>
	<DOCNO>NCT01496170</DOCNO>
	<brief_summary>This study ass safety pharmacodynamics three different dos MK-8931 , ß-secretase inhibitor , participant mild moderate Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacodynamics MK-8931 Participants With Alzheimer 's Disease ( MK-8931-010 AM1 P07820 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Body Mass Index ( BMI ) 18 35 Mild moderate Alzheimer 's Disease ( AD ) Clear history cognitive functional decline least one year either document medical record , document history informant know subject well Magnetic Resonance Image ( MRI ) scan consistent diagnosis AD Ability read 6th grade level history academic achievement and/or employment sufficient exclude mental retardation If applicable , stable dose acetylcholinesterase inhibitor and/or memantine least last 3 month Screening , willing remain dose duration trial Reliable trial partner/caregiver Willing provide blood sample Apolipoprotein E ( APOE ) genotyping In general good health ( AD ) Participant capable conceive and/or participant partner capable conceive willing use medically acceptable form contraception trial 3 month stop medication Exclusion criterion : History ( within 2 year prestudy visit ) current evidence neurological neurodegenerative disorder AD associate transient sustain alteration cognition Clinically significant abnormality serum vitamin B12 , folate , thyroid stimulate hormone ( TSH ) thyroxin 4 ( T4 ) . Vitamin B12 thyroid replacement therapy must stable dose least 2 month prior screen visit One preexisting risk factor Torsades de Pointes : New York Heart Association ( NYHA ) Functional Classification II IV heart failure ; Familial Long QT Syndrome ; Uncorrected hypokalemia Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug History spinal cord compression current abnormality lumbar region ( skin infection , developmental abnormality low spine , etc . ) History infectious disease within 4 week prior drug administration Human immunodeficiency virus ( HIV ) positive History hepatitis liver disease within 6 month screen History psychiatric personality disorder Evidence suicidality risk selfharm harm others History seizures epilepsy anticonvulsant use within last 5 year Screening History alcohol drug abuse past 2 year Donation blood past 60 day Previously receive study drug Currently participate another clinical study participate clinical study ( e.g. , laboratory clinical evaluation ) within 30 day baseline Member study staff family member study staff Demonstrated allergic reaction ( e.g. , food , drug , atopic reaction asthmatic episode ) History malignancy occur within 5 year immediately Screening , except subject adequately treat basal cell squamous cell skin cancer , situ cervical cancer , localize prostate carcinoma ; undergone potentially curative therapy evidence recurrence ≥1 year posttherapy , deem low risk recurrence her/his treat physician</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>